Ervogastat

Overview of the drug Ervogastat

Ervogastat
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Ervogastat is an investigational drug that acts as a diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor. It is being studied for its potential use in the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease characterized by inflammation and fat accumulation in the liver.

Mechanism of Action

Ervogastat functions by inhibiting the enzyme DGAT2, which plays a crucial role in the synthesis of triglycerides. By blocking this enzyme, Ervogastat reduces the formation of triglycerides, thereby decreasing fat accumulation in the liver. This mechanism is particularly beneficial in conditions like NASH, where excessive fat deposition leads to liver damage.

Clinical Development

Ervogastat is currently undergoing clinical trials to evaluate its efficacy and safety in patients with NASH. The drug has shown promise in preclinical studies, demonstrating a significant reduction in liver fat content and improvement in liver histology.

Potential Benefits

The primary benefit of Ervogastat is its ability to target the underlying metabolic disturbances in NASH. By reducing liver fat, it may help to alleviate inflammation and fibrosis, potentially slowing the progression of the disease. This could lead to improved liver function and a reduction in the risk of cirrhosis and liver-related complications.

Side Effects

As with any investigational drug, the safety profile of Ervogastat is still being established. Common side effects observed in clinical trials include mild gastrointestinal disturbances, such as nausea and diarrhea. Ongoing studies aim to further elucidate the long-term safety and tolerability of the drug.

Future Directions

Research on Ervogastat is focused on optimizing its therapeutic potential and understanding its role in the broader context of metabolic diseases. Future studies may explore its use in combination with other therapies to enhance treatment outcomes for patients with NASH and related conditions.

Related pages

• Non-alcoholic steatohepatitis
• Diacylglycerol O-acyltransferase 2
• Triglyceride